Stocks
Boston Scientific Financial Statements (BSX) |
||||||||||
| Boston Scientificsmart-lab.ru | % | 2023Q4 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 20.02.2024 | 21.02.2024 | 01.05.2024 | 01.08.2024 | 01.11.2024 | 01.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 3 725 | 3 725 | 3 856 | 4 120 | 4 209 | 15 910 | |||
| Operating Income, bln rub | 584.0 | 584.0 | 693.0 | 747.0 | 733.0 | 2 757 | ||||
| EBITDA, bln rub | ? | 1 016 | 883.0 | 984.0 | 812.0 | 1 058 | 3 737 | |||
| Net profit, bln rub | ? | 505.0 | 505.0 | 492.0 | 324.0 | 468.0 | 1 789 | |||
| OCF, bln rub | ? | 957.0 | 957.0 | 164.0 | 813.0 | -1 142 847 | -1 140 913 | |||
| CAPEX, bln rub | ? | 267.0 | 267.0 | 245.0 | 155.0 | 392.0 | 1 059 | |||
| FCF, bln rub | ? | 690.0 | 690.0 | -81.0 | 658.0 | -1 143 239 | -1 141 972 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 23.0 | 23.0 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 4.91% | 1.29% | ||||
| OPEX, bln rub | 1 961 | 1 961 | 1 954 | 1 838 | 1 969 | 7 722 | ||||
| Cost of production, bln rub | 1 147 | 1 147 | 1 209 | 1 535 | 1 561 | 5 452 | ||||
| R&D, bln rub | 363.0 | 363.0 | 366.0 | 383.0 | 407.0 | 1 519 | ||||
| Interest expenses, bln rub | 65.0 | 65.0 | 69.0 | 77.0 | 79.0 | 290.0 | ||||
| Assets, bln rub | 35 136 | 35 136 | 36 669 | 37 108 | 38 078 | 38 078 | ||||
| Net Assets, bln rub | ? | 19 281 | 19 281 | 19 925 | 20 371 | 20 708 | 20 708 | |||
| Debt, bln rub | 9 492 | 9 492 | 11 001 | 10 936 | 11 258 | 11 258 | ||||
| Cash, bln rub | 865.0 | 865.0 | 2 329 | 2 988 | 2 502 | 2 502 | ||||
| Net debt, bln rub | 8 627 | 8 627 | 8 672 | 7 948 | 8 756 | 8 756 | ||||
| Ordinary share price, rub | 57.8 | 57.8 | 68.5 | 77.0 | 83.8 | 52.5 | ||||
| Number of ordinary shares, mln | 1 465 | 1 465 | 1 468 | 1 471 | 1 473 | 1 473 | ||||
| Market cap, bln rub | 84 709 | 84 709 | 100 571 | 113 251 | 123 412 | 77 346 | ||||
| EV, bln rub | ? | 93 336 | 93 336 | 109 243 | 121 199 | 132 168 | 86 102 | |||
| Book value, bln rub | -1 109 | -1 109 | -273 | 557 | -79 | -79 | ||||
| EPS, rub | ? | 0.34 | 0.34 | 0.34 | 0.22 | 0.32 | 1.21 | |||
| FCF/share, rub | 0.47 | 0.47 | -0.06 | 0.45 | -776.3 | -775.4 | ||||
| BV/share, rub | -0.76 | -0.76 | -0.19 | 0.38 | -0.05 | -0.05 | ||||
| EBITDA margin, % | ? | 27.3% | 23.7% | 25.5% | 19.7% | 25.1% | 23.5% | |||
| Net margin, % | ? | 13.6% | 13.6% | 12.8% | 7.86% | 11.1% | 11.2% | |||
| FCF yield, % | ? | 2.01% | 2.01% | 1.54% | 1.55% | -925.3% | -1 476% | |||
| ROE, % | ? | 8.26% | 8.26% | 8.89% | 8.96% | 8.64% | 8.64% | |||
| ROA, % | ? | 4.53% | 4.53% | 4.83% | 4.92% | 4.70% | 4.70% | |||
| P/E | ? | 53.2 | 53.2 | 56.8 | 62.1 | 69.0 | 43.2 | |||
| P/FCF | 49.7 | 49.7 | 64.8 | 64.4 | -0.11 | -0.07 | ||||
| P/S | ? | 5.95 | 5.95 | 6.84 | 7.44 | 7.76 | 4.86 | |||
| P/BV | ? | -76.4 | -76.4 | -368.4 | 203.3 | -1 562 | -979.1 | |||
| EV/EBITDA | ? | 27.8 | 27.4 | 30.0 | 33.2 | 35.4 | 23.0 | |||
| Debt/EBITDA | 2.57 | 2.54 | 2.38 | 2.17 | 2.34 | 2.34 | ||||
| R&D/CAPEX, % | 136.0% | 136.0% | 149.4% | 247.1% | 103.8% | 143.4% | ||||
| CAPEX/Revenue, % | 7.17% | 7.17% | 6.35% | 3.76% | 9.31% | 6.66% | ||||
| Boston Scientific shareholders | ||||||||||
